查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1985569

溶瘤病毒療法市場：2026-2032年全球市場預測（按病毒類型、癌症適應症、給藥途徑和最終用戶分類）

Oncolytic Virus Therapies Market by Virus Type, Cancer Indication, Administration Route, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，溶瘤病毒療法市場價值將達到 1.5379 億美元，到 2026 年將成長至 1.8498 億美元，到 2032 年將達到 4.4483 億美元，年複合成長率為 16.38%。

主要市場統計數據
基準年 2025 1.5379億美元
預計年份：2026年 1.8498億美元
預測年份 2032 4.4483億美元
複合年成長率 (%) 16.38%

溶瘤病毒療法的策略架構：聚焦轉化潛力、生產實際情況、臨床試驗設計需求和生態系統促進因素

溶瘤病毒療法處於快速發展的病毒學、免疫腫瘤學和精準醫學的交叉領域，它提供了一種全新的作用機制，能夠選擇性地感染和裂解癌細胞，同時刺激抗腫瘤免疫。該領域已從概念驗證（PoC）臨床試驗發展到更為複雜的病毒基因組、有效載荷和遞送系統設計，旨在擴大治療範圍並解決固態腫瘤標靶治療的難題。隨著研發進程的推進，相關人員必須權衡生物學複雜性與實際考量，例如可擴展的生產、低溫運輸物流以及對能夠反映直接溶瘤效應和下游免疫介導反應的可靠臨床終點的需求。

近期技術進步、聯合治療策略、生產技術的改進以及法規環境的變化如何重新定義溶瘤病毒的開發和商業化。

溶瘤病毒療法的格局正在發生變化，重塑著競爭動態、臨床開發策略和投資重點。病毒工程技術的進步使得整合能夠調節腫瘤微環境、表達免疫刺激細胞激素或呈現腫瘤相關抗原以促進抗原擴散的有效載荷成為可能。這些技術變革，以及載體設計的改進，提高了腫瘤選擇性並降低了脫靶親和性，從而提高了治療指數，並將潛在適應症擴展到除淺層病變以外的其他部位。

本研究評估了預計 2025 年美國關稅和貿易政策變化對溶瘤病毒療法的供應鏈、製造決策和共同開發模式的影響。

預計2025年的關稅措施和貿易政策調整可能會對供應鏈、試劑採購和生技藥品生產的成本結構產生連鎖反應，並可能對溶瘤病毒研發者及其合作夥伴造成重大影響。病毒載體生產所需的許多關鍵材料，例如試劑、特殊塑膠、一次性生物反應器組件以及某些上游工程細胞培養基成分，均來自世界各地。進口關稅的提高、海關處理時間的延長或邊境檢查的加強都可能導​​致活性成分和生產材料的前置作業時間延長，並推高總體成本。

一種基於精確細分的觀點適應症的生物學特徵、病毒平台的特徵、給藥途徑和臨床護理環境與可行的開發策略聯繫起來。

基於細分的洞察揭示了不同適應症、病毒平台、給藥途徑和終端用戶中存在的微妙機會和限制，從而影響臨床策略和商業計劃。就癌症適應症而言，由於血腦障壁和局部腫瘤異質性，膠質母細胞瘤的遞送面臨獨特的挑戰。另一方面，儘管頭頸部癌症的免疫微環境複雜，但其瘤內注射部位相對容易取得；黑色素瘤則繼續作為模型適應症，其皮膚病變便於直接給藥和評估溶瘤活性。就病毒類型而言，基因改造病毒具有可設計有效載荷和安全開關等優勢，而野生型病毒則具有固有的親和性並能降低初始開發的複雜性。在基因改造平台中，腺病毒、單純皰疹病毒和痘苗病毒各自具有不同的親和性、有效載荷能力和安全性，需要根據每種適應症的特定生物學特徵進行客製化。

從全面的區域觀點檢驗法律規範、臨床基礎設施和生產能力如何影響全球主要市場腫瘤療法的發展。

區域趨勢在全球溶瘤病毒格局的形成中發揮核心作用，包括臨床試驗生態系統、製造地和監管合作。美洲受益於成熟的監管路徑、廣泛的臨床試驗網路以及來自創投和大型企業的巨額投資，但也面臨著激烈的生產能力競爭和複雜的醫保報銷環境，這些都影響著商業化策略。歐洲和中東及非洲（EMEA）的監管環境各不相同，各國衛生技術評估（HTA）框架和臨床基礎設施差異較大，因此需要採取個人化的監管措施和市場准入策略。此外，跨歐洲的臨床試驗舉措和成熟的學術研究中心仍然是該地區轉化科學發展的重要貢獻來源。

企業策略行動、夥伴關係模式和製造投資，旨在建立競爭優勢並實現腫瘤病毒專案的可擴展執行。

溶瘤病毒領域的企業正透過平台專業化、策略聯盟以及對生產規模化和監管合規的投資來實現差異化競爭。一些企業專注於快速有效載荷更換和模組化工程方法，以簡化跨多種腫瘤類型的臨床應用；而另一些企業則強調在特定適應症中進行全面的生物學最佳化，以增強給藥途徑和腫瘤微環境的特徵，從而提高溶瘤活性。早期研發公司與成熟的生物製藥企業之間的策略聯盟日益普遍，這有助於企業在無需完全內部垂直整合的情況下，獲得符合GMP標準的生產能力、監管專業知識和商業管道。

為決策者提供整合策略指導，以協調轉化科學、生產韌性、監管合作和市場進入計劃，並降低與專案進度相關的風險。

產業領導者必須採用一套整合的策略，將科學策略、營運準備和市場進入計畫相協調，以最大限度地提高轉換和商業性成功的潛力。應優先開發穩健的生物標記和轉化項目，以降低臨床假設風險、實現適應性試驗設計並支持監管諮詢。同時，必須儘早投資於製程開發和供應商選擇，以確保規模化生產時的可比性並最大限度地減少延誤。在條件允許的情況下，應尋求與免疫腫瘤學領域的合作夥伴建立策略夥伴關係，以設計利用互補機制的合理聯合治療試驗，並分擔監管和商業化風險。

一個透明的、跨學科的研究框架，結合文獻整合、專家諮詢和情境分析，以檢驗策略見解和操作建議。

本分析的調查方法包括對同行評審文獻、監管指導文件、臨床試驗註冊數據以及公開的技術白皮書進行嚴格審查，以構建科學進展和運營趨勢的全面視圖。此外，與臨床醫生、生物製程工程師、監管專家和契約製造公司高管的系統性專家諮詢，為供應策略、規模化挑戰和供應鏈脆弱性提供了切實可行的見解。在整合證據時，優先考慮現有的原始資料和監管申報文件，並透過與獨立專家意見和技術文件交叉核對來協調相互矛盾的數據。

簡要概述了將溶瘤病毒研究轉化為有意義的臨床結果所需的科學可能性、操作挑戰和合作途徑。

溶瘤病毒療法在免疫腫瘤學領域佔據著一個極具吸引力的細分市場，它既融合了創新的生物學機制，也面臨著特定的操作挑戰。科學進步使得病毒工程和活性成分遞送更加精準，但要將這些成果轉化為臨床和商業性的成功，需要對生產製造、供應鏈韌性和監管策略進行精心調整。根據適應症、病毒平台、給藥途徑和最終用戶環境進行策略性細分，可以提供有針對性的臨床開發和商業化路徑，從而提升患者獲益和企業投資回報。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：溶瘤病毒療法市場（依病毒類型分類）

  • 基因改造病毒
    • 腺病毒
    • 單純皰疹病毒
    • 牛痘病毒
  • 野生型病毒

第9章：溶瘤病毒療法市場（以癌症適應症分類）

  • 膠質母細胞瘤
  • 頭頸癌
  • 惡性黑色素瘤

第10章：溶瘤病毒療法市場（依給藥途徑分類）

  • 腫瘤內部
  • 靜脈

第11章 溶瘤病毒療法市場：以最終用戶分類

  • 醫院
  • 研究機構
  • 專科診所

第12章 溶瘤病毒療法市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 溶瘤病毒療法市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 溶瘤病毒療法市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國溶瘤病毒療法市場

第16章：中國溶瘤病毒療法市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amunbio Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • BioInvent International AB
  • Boehringer Ingelheim International GmbH
  • Calidi Biotherapeutics, Inc.
  • Candel Therapeutics
  • Daiichi Sankyo Company Ltd.
  • Elicera Therapeutics AB
  • EpicentRx, Inc.
  • Genelux Corporation
  • Hookipa Pharma Inc.
  • Imvaq Therapeutics
  • Istari Oncology, Inc.
  • Johnson & Johnson Services, Inc.
  • Lokon Pharma AB
  • Merck & Co., Inc.
  • Orgenesis Inc.
  • Pfizer, Inc.
  • Protheragen Inc.
  • Seneca Therapeutics, Inc.
  • Takara Bio Inc.
  • TILT Biotherapeutics
  • Treovir LLC
  • Wuhan Binhui Biotechnology Co Ltd
Product Code: MRR-007C484E5E64

The Oncolytic Virus Therapies Market was valued at USD 153.79 million in 2025 and is projected to grow to USD 184.98 million in 2026, with a CAGR of 16.38%, reaching USD 444.83 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 153.79 million
Estimated Year [2026] USD 184.98 million
Forecast Year [2032] USD 444.83 million
CAGR (%) 16.38%

A strategic framing of oncolytic virus therapies highlighting translational promise, manufacturing realities, clinical design imperatives and ecosystem enablers

Oncolytic virus therapies represent a rapidly evolving intersection of virology, immuno-oncology, and precision medicine, offering a novel mechanism of action that selectively infects and lyses tumor cells while stimulating antitumor immunity. The field has matured from proof-of-concept clinical demonstrations to more sophisticated engineering of viral genomes, payloads, and delivery systems that aim to broaden therapeutic windows and address solid tumor accessibility challenges. As development pathways advance, stakeholders must reconcile biological complexity with practical considerations such as scalable manufacturing, cold-chain logistics, and the necessity of robust clinical endpoints that capture both direct oncolytic effects and downstream immune-mediated responses.

Translational success often hinges on the integration of preclinical mechanistic insight with pragmatic trial design. Iterative learning from early-phase studies has refined patient selection strategies, intratumoral and systemic dosing approaches, and combinatorial regimens with checkpoint inhibitors or other immunomodulators. Continued progress requires tight alignment between scientific innovation and regulatory engagement to establish meaningful safety monitoring frameworks and to validate biomarkers that predict response or resistance. Moreover, public and private research institutions, clinical trial networks, and specialized contract manufacturing organizations are forming the operational backbone that will determine the pace at which promising candidates can move from bench to larger cohort evaluation.

Looking forward, the trajectory of oncolytic virus therapies will depend not only on scientific breakthroughs but on the ecosystem's ability to scale manufacturing, secure supply chains for viral vectors and raw materials, and navigate evolving reimbursement and policy environments. Stakeholders that proactively address these translational and operational imperatives will be better positioned to convert biological potential into clinically actionable therapeutics.

How recent technological advances, combination therapy strategies, manufacturing improvements, and regulatory evolutions are redefining oncolytic virus development and commercialization

The landscape for oncolytic virus therapies is shifting in ways that reconfigure competitive dynamics, clinical development strategies, and investment priorities. Advances in viral engineering now enable the incorporation of payloads that modulate tumor microenvironments, express immune-stimulatory cytokines, or present tumor-associated antigens to enhance antigen spreading. These technological shifts are complemented by improved vector design to enhance tumor selectivity and to limit off-target tropism, thereby improving therapeutic indices and expanding potential indications beyond accessible superficial lesions.

Concurrently, clinical strategy is evolving from monotherapy proofs toward combination regimens where oncolytic agents act synergistically with immune checkpoint inhibitors, adoptive cell therapies, or targeted agents. This shift requires more complex trial designs and collaborative networks to test rational combinations and dose sequencing. On the operations side, improvements in GMP-compliant manufacturing and fill-finish processes are enabling higher-quality and more reproducible viral product batches, while emerging contract development and manufacturing partnerships are offloading capital intensity from smaller biotechs. Investor expectations are also changing: funders increasingly prioritize programs with clear biomarker strategies and manufacturability, favoring platforms that demonstrate scalability and regulatory engagement.

Finally, regulatory frameworks and payor dialogues are adapting to the unique attributes of oncolytic modalities, with agencies showing openness to innovative endpoints and adaptive trial schemas when supported by strong mechanistic rationale and safety data. Taken together, these transformative shifts are creating an environment where scientific novelty must be matched by operational maturity and strategic clinical collaborations to achieve durable commercial and patient impact.

Assessing how anticipated United States tariffs and trade policy shifts in 2025 could reshape supply chains, manufacturing decisions, and collaborative models for oncolytic therapies

Anticipated tariff measures and trade policy adjustments in 2025 are likely to have ripple effects on supply chains, reagent sourcing, and the cost structures of biologics manufacturing that materially influence oncolytic virus developers and their partners. Many critical inputs for viral vector production-including reagents, specialized plastics, single-use bioreactor components, and certain upstream cell culture media constituents-are sourced globally; any increase in import duties, customs processing times, or border checks can translate into longer lead times and higher landed costs for active pharmaceutical ingredients and manufacturing supplies.

Moreover, tariffs that alter the relative attractiveness of regional sourcing may accelerate reshoring or near-shoring strategies, prompting sponsors to reassess supplier portfolios and invest in redundant sourcing to mitigate disruption risk. This change can lead to short- and medium-term capital allocation toward local manufacturing capacity or in-country fill-finish services. In parallel, contract manufacturing organizations may pass through higher input costs to clients, affecting program budgets and potentially the timing of trial initiation. Regulatory compliance burdens can also be affected if tariff-driven supply chain modifications necessitate changes in supplier qualifications or material provenance documentation, requiring additional comparability assessments for biologics.

Trade policy shifts can also influence collaborative models. Cross-border academic-industry partnerships that rely on rapid exchange of biological materials and analytical services may face administrative friction if new customs or licensing requirements are introduced. Such constraints can slow translational timelines and raise the value of digital and remote collaborations, in silico modeling, and local clinical trial capacity. Finally, the cumulative impact of tariff changes will disproportionately affect early-stage developers and academic spin-outs with limited procurement scale, making strategic procurement planning and supplier diversification essential for program resilience.

Precision segmentation-driven perspectives that link indication biology, viral platform attributes, delivery routes, and clinical care settings to actionable development strategies

Segmentation-informed insights reveal nuanced opportunities and constraints across indications, viral platforms, administration routes, and end users that influence clinical strategy and commercial planning. When considering cancer indications, glioblastoma presents unique delivery challenges due to the blood-brain barrier and localized tumor heterogeneity, head and neck cancers offer relatively accessible intratumoral injection sites with complex immune microenvironments, and melanoma continues to serve as a model indication where cutaneous lesions facilitate direct administration and oncolytic activity assessment. In terms of virus type, genetically modified viruses bring the advantage of engineered payloads and safety switches, while wild type viruses can offer innate tropism and lower initial development complexity; within genetically modified platforms, adenovirus, herpes simplex virus, and vaccinia virus each offer distinct tissue tropisms, payload capacities, and safety profiles that must be aligned to indication-specific biology.

Administration route choices between intratumoral and intravenous approaches materially impact trial design, patient selection, and manufacturing specifications. Intratumoral administration enables high local viral titers and reduced systemic exposure but limits applicability to accessible lesions, whereas intravenous delivery offers the potential for treating disseminated disease but faces challenges of systemic neutralization, off-target sequestration, and altered biodistribution. End-user segmentation across hospitals, research institutes, and specialty clinics shapes commercial access pathways and service delivery models. Hospitals and specialized oncology centers offer integrated care and advanced interventional capabilities for intratumoral procedures, research institutes drive early translational studies and investigator-initiated trials, and specialty clinics can support routine administration workflows and patient monitoring for outpatient regimens.

Taken together, these segmentation elements underscore the importance of aligning viral platform selection, payload engineering, and delivery strategy to the biological and operational realities of each indication and care setting. Strategic decisions must balance the biological rationale with practical implementation constraints to optimize the pathway from clinical validation to scalable clinical use.

A comprehensive regional lens exploring how regulatory frameworks, clinical infrastructure, and manufacturing capabilities influence oncolytic therapy development across major global markets

Regional dynamics play a central role in shaping clinical trial ecosystems, manufacturing footprints, and regulatory interactions across the global oncolytic virus landscape. The Americas benefit from established regulatory pathways, extensive clinical trial networks, and deep venture and corporate investment but also face concentrated competition for manufacturing capacity and complex reimbursement environments that influence commercialization strategies. Europe, Middle East & Africa present diverse regulatory landscapes where country-specific health technology assessment frameworks and clinical infrastructure variability drive tailored regulatory and market-access approaches; collaborative pan-European trial initiatives and well-established academic centers continue to be important contributors to translational science in the region.

In Asia-Pacific, rapidly expanding clinical trial capacity, increasing biotech investment, and strategic government support for biotechnology infrastructure create fertile conditions for accelerated clinical development and local manufacturing expansion. Differences in patient demographics, prevalent cancer indications, and treatment paradigms across regions necessitate targeted clinical development strategies, and regional manufacturing hubs are becoming increasingly relevant as sponsors weigh the benefits of near-market production against tariff and logistics considerations. Cross-regional partnerships and localized regulatory engagement strategies are instrumental in navigating differences in trial endpoints, data requirements, and approval timelines.

Therefore, regional insight should inform not only where trials are conducted but how manufacturing, regulatory planning, and commercial strategies are orchestrated to maximize patient access and program resilience across disparate healthcare systems.

Strategic corporate behaviors, partnership models, and manufacturing investments that define competitive advantage and enable scalable oncolytic virus program execution

Companies operating in the oncolytic virus sector are differentiating through platform specialization, strategic collaborations, and investments in manufacturing scale-up and regulatory engagement. Some organizations are focusing on modular engineering approaches that enable rapid payload swaps and streamlined clinical translation across multiple tumor types, while others emphasize deep biological optimization for specific indications where delivery routes and tumor microenvironment characteristics favor oncolytic activity. Strategic collaborations between early-stage developers and established biologics manufacturers have become commonplace, facilitating access to GMP capacity, regulatory expertise, and commercial channels without necessitating full in-house vertical integration.

Investment patterns also show that firms prioritizing clear biomarker development programs and translational data tend to attract more strategic interest from partners seeking combination therapy opportunities. Contract development and manufacturing organizations are evolving their service offerings to include viral vector-specific process development, analytical method validation, and virus-specific comparability assessments, thereby lowering the barrier to clinical manufacturing for smaller companies. Additionally, licensing deals and codevelopment agreements frequently include provisions for phased milestones tied to clinical proof points, reflecting a pragmatic balance between risk-sharing and incentivizing accelerated development.

From a competitive perspective, companies that can demonstrate robust supply chain strategies, validated manufacturing platforms, and proactive regulatory interactions will be preferentially positioned to execute complex combination trials and to secure sustainable commercial pathways. Organizational agility in responding to clinical learnings and in pivoting platform applications remains a core differentiator in a field where scientific understanding and operational demands evolve rapidly.

An integrated strategic playbook for decision-makers that aligns translational science, manufacturing resilience, regulatory engagement, and market access planning to de-risk program progression

Industry leaders should adopt an integrated playbook that aligns scientific strategy with operational readiness and market access planning to maximize the probability of translational and commercial success. Prioritize the development of robust biomarker and translational programs that can de-risk clinical hypotheses, enable adaptive trial designs, and support regulatory discussions; simultaneously, invest early in process development and vendor qualification to ensure comparability and minimize delays during scale-up. Where feasible, pursue strategic collaborations with immuno-oncology partners to design rational combination studies that leverage complementary mechanisms and to share regulatory and commercialization risk.

Operationally, build redundant supply chains and establish relationships with multiple qualified suppliers and contract manufacturers to mitigate tariff-related and logistical disruptions. Tailor clinical development pathways to indication- and region-specific realities, selecting administration routes and endpoints that optimize signal detection and patient enrollment feasibility. Engage payors and health technology assessment bodies early to understand evidence expectations and to design health-economic data collection approaches that support future reimbursement discussions. Finally, maintain active regulatory dialogue to clarify expectations around safety monitoring, manufacturing comparability, and accelerated approval pathways where appropriate, translating scientific momentum into durable patient access.

A transparent, multidisciplinary research framework combining literature synthesis, expert consultations, and scenario analysis to validate strategic insights and operational recommendations

The research methodology underpinning this analysis combined a rigorous review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly available technical white papers to construct a holistic view of scientific progress and operational trends. In addition, structured expert consultations with clinicians, bioprocess engineers, regulatory affairs specialists, and contract manufacturing executives informed practical considerations around delivery strategies, scale-up challenges, and supply chain vulnerabilities. Evidence synthesis prioritized primary sources and regulatory filings where available, and conflicting data points were reconciled through triangulation across independent expert perspectives and technical documentation.

Analytical approaches included qualitative thematic analysis of translational challenges, operational gap mapping to identify bottlenecks in manufacturing and logistics, and scenario-based assessment of policy impacts on supply chains and collaborative models. Ethical standards guided the selection and interpretation of clinical data, with careful attention paid to safety signals, patient population heterogeneity, and endpoint relevance. Finally, recommendations were stress-tested against real-world operational constraints to ensure that proposed actions are implementable within typical development timelines and resource envelopes.

A concise synthesis emphasizing the scientific promise, operational imperatives, and collaborative pathways necessary to translate oncolytic virus research into meaningful clinical impact

Oncolytic virus therapies occupy a compelling niche within the broader immuno-oncology landscape, balancing innovative biological mechanisms with tangible operational challenges. The science has progressed to enable more precise viral engineering and payload delivery, but translation to clinical and commercial success requires careful orchestration of manufacturing, supply chain resilience, and regulatory strategy. Strategic segmentation by indication, virus platform, administration route, and end-user setting informs targeted clinical development and commercialization pathways that improve the likelihood of patient benefit and organizational return on investment.

Policymakers and industry stakeholders must remain attentive to external factors such as trade policy and regional manufacturing dynamics that can influence program timelines and cost structures. By adopting integrated development strategies that pair scientific rigor with operational foresight, organizations can better navigate the complexity inherent in bringing oncolytic therapies from concept to clinic. Continued collaboration across academic centers, industry partners, contract manufacturers, and regulators will be essential to realize the full potential of oncolytic modalities for patients with hard-to-treat cancers.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oncolytic Virus Therapies Market, by Virus Type

  • 8.1. Genetically Modified Virus
    • 8.1.1. Adenovirus
    • 8.1.2. Herpes Simplex Virus
    • 8.1.3. Vaccinia Virus
  • 8.2. Wild Type Virus

9. Oncolytic Virus Therapies Market, by Cancer Indication

  • 9.1. Glioblastoma
  • 9.2. Head And Neck Cancer
  • 9.3. Melanoma

10. Oncolytic Virus Therapies Market, by Administration Route

  • 10.1. Intratumoral
  • 10.2. Intravenous

11. Oncolytic Virus Therapies Market, by End User

  • 11.1. Hospitals
  • 11.2. Research Institutes
  • 11.3. Specialty Clinics

12. Oncolytic Virus Therapies Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Oncolytic Virus Therapies Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Oncolytic Virus Therapies Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Oncolytic Virus Therapies Market

16. China Oncolytic Virus Therapies Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Amunbio Inc.
  • 17.6. Astellas Pharma Inc.
  • 17.7. AstraZeneca PLC
  • 17.8. BioInvent International AB
  • 17.9. Boehringer Ingelheim International GmbH
  • 17.10. Calidi Biotherapeutics, Inc.
  • 17.11. Candel Therapeutics
  • 17.12. Daiichi Sankyo Company Ltd.
  • 17.13. Elicera Therapeutics AB
  • 17.14. EpicentRx, Inc.
  • 17.15. Genelux Corporation
  • 17.16. Hookipa Pharma Inc.
  • 17.17. Imvaq Therapeutics
  • 17.18. Istari Oncology, Inc.
  • 17.19. Johnson & Johnson Services, Inc.
  • 17.20. Lokon Pharma AB
  • 17.21. Merck & Co., Inc.
  • 17.22. Orgenesis Inc.
  • 17.23. Pfizer, Inc.
  • 17.24. Protheragen Inc.
  • 17.25. Seneca Therapeutics, Inc.
  • 17.26. Takara Bio Inc.
  • 17.27. TILT Biotherapeutics
  • 17.28. Treovir LLC
  • 17.29. Wuhan Binhui Biotechnology Co Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VACCINIA VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VACCINIA VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VACCINIA VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY WILD TYPE VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY WILD TYPE VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY WILD TYPE VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HEAD AND NECK CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HEAD AND NECK CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRATUMORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRATUMORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRATUMORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 105. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 107. GCC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 123. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 124. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 125. G7 ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 129. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 130. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 131. NATO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)